Labcorp Cash Flow Statement
LH / Health Care|15 years of annual SEC 10-K data (FY2011-FY2025)
Covers operating cash flow, capital expenditures, free cash flow, share buybacks, and dividends paid across 15 fiscal years. All figures from audited SEC 10-K filings.
Labcorp generated $1.6B in operating cash flow and $1.2B in free cash flow in FY2025. Free cash flow margin was 8.6% of revenue.
Based on SEC 10-K filings.
Key Data Points
- High Piotroski F-Score: 8/9 (strong financial health signals)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 | FY2012 | FY2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | $876.5M | $746.0M | $418.0M | $1.3B | $2.4B | $883.7M | $823.8M | $883.7M | $1.2B | $711.8M | $437.6M | $113.1M | $573.8M | $583.1M | $519.7M |
| Depreciation & Amortization | $681.1M | $643.5M | $577.3M | $537.2M | $577.0M | $552.1M | $577.2M | $552.1M | $533.2M | $499.2M | $457.8M | $245.5M | $230.1M | $229.8M | $231.4M |
| Operating Cash Flow | $1.6B | $1.6B | $1.3B | $2.0B | $3.1B | $1.3B | $1.4B | $1.3B | $1.5B | $1.2B | $982.4M | $739.0M | $818.7M | $841.4M | $855.6M |
| Capital Expenditures | $434.5M | $489.9M | $453.6M | $429.3M | $421.5M | $379.8M | $400.2M | $379.8M | $312.9M | $278.9M | $255.8M | $203.5M | $202.2M | $173.8M | $145.7M |
| Free Cash Flow | $1.2B | $1.1B | $874.1M | $1.5B | $2.7B | $925.6M | $1.0B | $925.6M | $1.2B | $918.2M | $726.6M | $535.5M | $616.5M | $667.6M | $709.9M |
| Share Buybacks | $450.0M | $250.1M | $1.0B | $1.1B | $1.7B | $700.0M | $450.0M | $700.0M | $338.1M | $43.9M | $0 | $269.0M | $1.0B | $516.5M | $643.9M |
| Dividends Paid | $240.7M | $243.1M | $254.0M | $195.2M | - | - | - | - | - | - | - | - | - | - | - |
| FCF Margin | 8.6% | 8.4% | 7.2% | 12.9% | 20.5% | 8.2% | 9.0% | 8.2% | 11.5% | 9.6% | 8.4% | 8.9% | 10.6% | 11.8% | 12.8% |